Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $1,008.96 Consensus Price Target from Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been given a consensus recommendation of “Moderate Buy” by the twenty-two research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, sixteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $1,027.55.

REGN has been the topic of a number of recent analyst reports. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. Bank of America lifted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. Finally, StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th.

Insider Activity at Regeneron Pharmaceuticals

In related news, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,467,684. The disclosure for this sale can be found here. Insiders sold a total of 61,971 shares of company stock valued at $61,217,654 in the last three months. Company insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Sierra Summit Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $1,011,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $749,000. Public Employees Retirement Association of Colorado grew its stake in shares of Regeneron Pharmaceuticals by 16.0% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock worth $14,118,000 after acquiring an additional 2,220 shares during the period. Exchange Traded Concepts LLC grew its stake in shares of Regeneron Pharmaceuticals by 32.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after acquiring an additional 1,221 shares during the period. Finally, Congress Wealth Management LLC DE bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $271,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $1,051.03 on Thursday. The firm has a market cap of $115.81 billion, a PE ratio of 31.05, a price-to-earnings-growth ratio of 2.17 and a beta of 0.13. Regeneron Pharmaceuticals has a 12-month low of $688.52 and a 12-month high of $1,081.17. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The company’s fifty day simple moving average is $984.27 and its two-hundred day simple moving average is $951.01.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 37.23 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.